Invesco Ltd. Sells 4,475,485 Shares of OPKO Health, Inc. (NASDAQ:OPK)

Invesco Ltd. trimmed its position in OPKO Health, Inc. (NASDAQ:OPK) by 74.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,554,489 shares of the biotechnology company’s stock after selling 4,475,485 shares during the period. Invesco Ltd. owned approximately 0.23% of OPKO Health worth $2,285,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Barclays PLC increased its position in OPKO Health by 154.5% in the 3rd quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock valued at $810,000 after buying an additional 329,870 shares in the last quarter. Norges Bank acquired a new position in OPKO Health during the 4th quarter valued at about $1,657,000. Raymond James Financial Inc. acquired a new position in OPKO Health during the 4th quarter valued at about $221,000. Y Intercept Hong Kong Ltd acquired a new position in OPKO Health during the 4th quarter valued at about $102,000. Finally, KLP Kapitalforvaltning AS acquired a new position in OPKO Health during the 4th quarter valued at about $109,000. 64.63% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

OPK has been the subject of a number of analyst reports. JPMorgan Chase & Co. initiated coverage on OPKO Health in a research note on Friday. They set a “neutral” rating for the company. Barrington Research restated an “outperform” rating and issued a $2.25 target price on shares of OPKO Health in a research note on Wednesday, March 12th. StockNews.com upgraded OPKO Health from a “sell” rating to a “hold” rating in a research note on Monday, March 3rd. Finally, HC Wainwright restated a “buy” rating and issued a $3.00 target price on shares of OPKO Health in a research note on Monday, April 7th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $2.75.

OPKO Health Price Performance

OPKO Health stock opened at $1.41 on Tuesday. The business’s 50 day simple moving average is $1.64 and its 200 day simple moving average is $1.57. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. OPKO Health, Inc. has a 12 month low of $1.15 and a 12 month high of $2.04. The company has a market cap of $946.89 million, a price-to-earnings ratio of -7.42 and a beta of 1.78.

OPKO Health (NASDAQ:OPK) last issued its earnings results on Thursday, February 27th. The biotechnology company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.08) by $0.09. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The business had revenue of $183.60 million during the quarter, compared to the consensus estimate of $155.42 million. Sell-side analysts forecast that OPKO Health, Inc. will post -0.25 EPS for the current year.

Insiders Place Their Bets

In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 125,000 shares of the company’s stock in a transaction dated Thursday, April 10th. The stock was purchased at an average price of $1.36 per share, for a total transaction of $170,000.00. Following the transaction, the chief executive officer now owns 214,001,448 shares in the company, valued at $291,041,969.28. The trade was a 0.06 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders purchased a total of 767,434 shares of company stock worth $1,238,312 in the last quarter. 49.69% of the stock is owned by company insiders.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.